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Abstract 
Hemangiopericytoma (HPC) is a rare sarcomatous tumor arising from pericytes, a support 
cell found in blood vessels. These tumors can occur throughout the body, particularly in 
the lower extremities and retroperitoneum. In rare circumstances, HPCs can arise from 
the meninges. In these cases, they behave similar to meningiomas, in particular 
angiomatous meningiomas, but tend to be more aggressive and are likely to recur. 
Treatment usually focuses on surgical resection and radiotherapy with possible inclusion 
of chemotherapy for control of recurrent disease. We describe a case of recurrent right 
temporal HPC that first manifested as a paraneoplastic syndrome of oncogenic 
osteomalacia. Despite maximum therapy, this patient experienced multiple recurrences 
of the tumor, and immunohistochemical analysis revealed overexpression of platelet-
derived growth factor receptor, a member of the SRC-related tyrosine kinases. After 
multiple recurrences, the patient’s tumor has been stable with treatment with 
monotherapy utilizing molecularly targeted therapy to SRC-related tyrosine kinases. This 
is the first case report of the treatment of recurrent meningeal HPC with molecularly 
targeted therapy to SRC-related tyrosine kinases.  
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Introduction 
Hemangiopericytomas (HPCs) were first categorized by Stout as malignant tumors 
arising from the blood vessels and described as a sarcoma [1]. The cell of origin is thought 
to be the pericyte which interacts with endothelial cells and is critical for blood vessel 
maintenance [2]. HPCs are extremely rare and occur usually outside the central nervous 
system (CNS) with the most common sites being the lower extremities or 
retroperitoneum [3]. In rare instances, HPCs can arise from the meninges in the CNS and 
can be confused with solitary fibrous tumors [1, 4]. In the case series by Guthrie and et al. 
[4], most patients with meningeal HPCs are adults, usually in the 5th decade. 
Furthermore, presentation of the HPC was primarily related to location of the sarcoma. 
The primary mode of treatment included surgical resection, followed by radiotherapy, 
but, unfortunately, HPCs can both recur and metastasize. 
Paraneoplastic syndromes have been reported as the initial presentation or part of the 
diagnosis of HPC. The paraneoplastic syndrome of oncogenic osteomalacia, defined by 
hypophosphatemia, hyperphosphaturia, and osteomalacia, has been seen in soft tissue 
sarcomas, including HPCs [5]. Treatment of HPC is often difficult as the tumors tend to 
recur locally. While the roles of surgical resection and radiotherapy are well understood, 
the role of chemotherapy in the treatment of multiple recurrences of HPC has not been 
well established [6]. We present a case of a male with a right sphenoid wing HPC who 
presented initially with the paraneoplastic syndrome of oncogenic osteomalacia 9 years 
before his HPC diagnosis. After multiple recurrences, he has been stabilized with 
molecularly targeted monotherapy utilizing dasatinib, a small molecule that inhibits SRC-
related tyrosine kinases. 
Case Report 
A 22-year-old healthy male presented with diffuse bone pain. On clinical laboratory testing, serum 
phosphorus was extremely low at 0.8 mg/dl. The patient was later found to have hyperphosphaturia and 
hypercalcemia and was diagnosed with hypophosphatemic osteomalacia. Etiology of the 
hypophosphatemic osteomalacia was unclear at that time, but the patient was treated with neutral 
sodium phosphate and dihydrotachysterol, which improved his pain. He also began to experience sharp 
pain at the right retro-orbital region and right-sided hearing loss. Later, placement of a right 
tympanostomy was attempted because of presumed chronic otitis media and a vascular tumor was 
visualized in his right middle ear. Initial biopsy was only remarkable for granular tissue. At 30 years of 
age, he developed numbness at the right temple and a head CT revealed a mass arising from the right 
sphenoid wing that infiltrated into the floor of the middle cranial fossa. Embolization was performed 
which was followed by a partial resection of the mass via right temporal craniotomy. Pathology showed 
HPC (WHO grade II) (fig. 1). The previous diagnosis of hypophosphatemic osteomalacia was 
attributed to a paraneoplastic presentation of oncogenic osteomalacia due to HPC. Within 4 years from 
initial tumor diagnosis, the tumor recurred, and the patient was found to have a right seventh nerve 
palsy. A second embolization was performed for this recurrent tumor, and the patient was followed with 
serial scans. Approximately 3 years after this resection, the tumor increased in size. Despite partial 
resection, the patient continued to have osteomalacia and hypophosphatemia. He was also noted to 
have brown tumors associated with hyperparathyroidism involving the mandible and the right hand. A 
third embolization was performed followed by a second partial resection with craniotomy. Pathology 
was consistent with HPC (WHO grade II). Octreoscan (indium-labeled pentetreotide scan) showed 
active uptake by the remaining tumor. He received octreotide injections for the next 3 years. After 
identification of the brown tumors, the patient underwent a total parathyroidectomy with 
reimplantation of one parathyroid into the left arm to address the tertiary hyperparathyroidism. After 3 
years of octreotide treatment, he developed déjà vu episodes (consistent with possible seizure activity) 
and magnetic resonance imaging (MRI) revealed progression of his tumor. He underwent a gamma 
knife procedure and was followed with serial scans. When the mass recurred approximately 2 years 
later, he had fractionated stereotactic radiotherapy to the right temporal mass. Eleven months after 
fractionated radiotherapy, he participated in a clinical trial for 5 months using somatostatin receptor  
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radiopharmaceutical called (90) Y-dodecane-tetrateaacetic acid-Phe1-Tyr3-octreotide. After completion 
of 3 six-week cycles of this therapy, he was followed with serial MRI scans. Approximately 1 year later, 
he developed worsening right facial weakness and was found to have recurrent tumor extending into the 
middle ear cavity, external auditory canal, intratemporal fossa, inferior orbital fissure, and the anterior 
aspect of the cavernous sinus. There was no change in his treatment course and he continued to be 
followed with serial scans until 4 years later. At that time (age 56 years), he underwent a right temporal 
craniotomy with partial resection for recurrent tumor (fig. 2a and b). Testing of his tumor from the 
second resection showed high immunoreactivity to platelet-derived growth factor receptor (PDGFR), 
therefore, dasatinib was considered for monotherapy. After the third resection, he was placed on 
dasatinib at 70 mg orally once a day and has been followed with serial scans. Currently, he has been on 
monotherapy with dasatinib for 2 years and continues to be both clinically and radiographically stable 
by MRI an dFDG-PET (fig. 2c). 
Discussion 
HPC is a rare malignancy that is believed to arise from pericytes, a support cell of the 
vasculature that interacts with endothelial cells. Usually, HPCs present in the lower 
extremities or retroperitoneum, but in some circumstances, they can occur within the 
CNS. When they involved the CNS, HPCs were previously described as angioblastic 
meningiomas, as the tumors were uniquely vascular and arose from the meninges [7]. 
Now, these two entities are considered to be separate, but similar, malignancies. Two case 
series of meningeal HPCs have described the presentation, course, and treatment of these 
rare tumors [4, 8]. In both case series, patients present in adulthood, with a median 
occurrence of HPC in the fifth decade. The initial presentation was usually focal 
neurological signs, and headache was also a prominent symptom that led to the diagnosis 
of meningeal HPCs. A majority of patients experienced recurrences of their tumors 
within a range of 60.6–76%. In rare circumstances, clinicians have documented that HPCs 
can metastasize with sites including the bone, liver, lung, and peritoneum, with a 5-year 
metastasis rate at 33% [4]. 
Treatment of meningeal HPCs is similar to meningiomas in that surgical resection is 
utilized at the initial presentation if amenable to surgery. Total resection is often hindered 
by the extensive vasculature of the tumor, and pre-embolization of the tumor before 
resection can prevent blood loss [9]. Radiotherapy is used post-operatively to prevent 
recurrence, but in a study by Dufour et al. [10], radiotherapy did not change the rate of 
metastases. The utility of chemotherapy in the treatment of meningeal HPCs is unclear. 
Doxorubin-based regimens have been used, but have yet to establish a clear role in the 
treatment of HPC [6]. With the recurrent nature of HPCs as seen in our current case 
report, there is a vital need for better treatments of persistently recurrent HPCs. One 
possible therapy could be the use of molecularly targeted therapies based on the pattern of 
expression of growth factors in HPCs. A recent report showed that angiomatous 
meningiomas and HPCs often overexpress PDGFR as detected by immunohistochemistry 
[11]. Therefore, it is provocative that this overexpression of PDGFR could be utilized to 
treat recurrent angiomatous meningiomas and HPCs.  
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC 
family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ [12, 13]. Dasatinib is 
approved by the Federal Drug Administration for the treatment of chronic myelogenous 
leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia [14, 15]. In 
our case presentation, the patient’s tumor tissue showed overexpression of PDGFR based 
on immunohistochemical analysis. Because of dasatinib’s ability to inhibit PDGFR, we 
initiated therapy with this agent. Since initiation of therapy, the patient has tolerated that 
therapy well with little toxicity and has continued on monotherapy for over 2 years. MRI  
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and FDG-PET imaging reveal no evidence of recurrent disease at this time. Thus, this 
suggests that there may be a role for targeted therapy in the treatment of HPCs. While this 
tumor is extremely rare and it is thus difficult to evaluate the drug’s effectiveness in 
clinical trials, the further use of dasatinib in the treatment of recurrent HPC may be 
warranted.  
In conclusion, our case report provides a first example of treatment of recurrent HPC 
with molecular targeted monotherapy. 
 
 
 
 
 
Fig. 1. a Initial biopsy of HPC composed of elongated spindle- to carrot-shaped cells with pleomorphic 
nuclei and eosinophilic cytoplasm. Dilated vascular channels lined by flattened endothelium are evident. 
A mitotic figure is noted centrally (HE, ×10). b HPC is characterized by large dilated ‘staghorn’ vascular 
channels (HE, ×10). 
 
 
 
Fig. 2. Contrast-enhancing right temporal lobe mass. a Recurrent mass before third partial resection 
and craniotomy. Pathology was consistent with HPC. b After third craniotomy and partial resection. 
c After 1 year of monotherapy with dasatinib (axial T1 with gadolinium enhancement MRI images). 
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